BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will present a corporate overview at the upcoming 2025 BIO International Convention taking place in Boston, MA from June 16 – 19, 2025. Dr. Mazzo’s pre ...

Targeted Therapy Delivered Corporate Presentation | May 8, 2025 Nasdaq: LSTA www.lisata.com © Lisata Therapeutics, Inc. 2025. All rights reserved. Disclosure Forward-looking statements advisory This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, futur ...

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants John Menditto - VP of IR and Corporate Communications David Mazzo - President and CEO James Nisco - SVP of Finance and Treasury and Chief Accounting Officer Kristen Buck - EVP of R&D and Chief Medical Officer Conference Call Participants Kemp Dolliver - Brookline Capital Market Pete Enderlin - MAZ Partners Operator Welcome to the Lisata Therapeutics First Quarter 2025 Financial Results and Bu ...

Lisata Therapeutics (LSTA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants John Menditto - Vice President of Investor Relations & Corporate CommunicationsDavid Mazzo - President and Chief Executive OfficerJames Nisco - SVP of Finance, Treasurer, CAO & Principal Financial & Accounting OfficerKristen Buck - EVP of R&D and Chief Medical OfficerSara Nik - Senior Associate - Equity ResearchPeter Enderlin - Portfolio Manager Conference Call Participants Kemp Dolliver - Director - Research & Se ...

Lisata Therapeutics (LSTA) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Welcome to the Losada Therapeutics First Quarter twenty twenty five Financial Results and Business Update Conference Call. Currently, participants are in listen only mode. Following management's prepared remarks, we will hold a Q and A session. As a reminder, this call is being recorded today, Thursday, 05/08/2025. I will now turn the call over to John Mendito, Vice President of Investor Relations and Corporate Communications ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from __________________ to _________________________ Commission File Number 001-33650 LISATA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delawar ...

Forward-looking statements advisory Exhibit 99.2 Targeted Therapy Delivered Corporate Presentation | May 8, 2025 Nasdaq: LSTA www.lisata.com © Lisata Therapeutics, Inc. 2025. All rights reserved. Disclosure This presentation contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding st ...

Encouraging results of Cohort A data from the ASCEND trial presented at ASCO-GI 2025;Cohort B results from the ASCEND trial accepted for an oral presentation at ESMO-GI 2025 Cash runway extending into the third quarter of 2026 with no debt Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatm ...

BASKING RIDGE, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the Company will report its financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, after the close of trading and will host a conference call at 4:30 p.m. Eastern time. Those wishing to partic ...